United Therapeutics (UTHR)
(Delayed Data from NSDQ)
$237.00 USD
+2.53 (1.08%)
Updated Apr 24, 2024 04:00 PM ET
After-Market: $236.96 -0.04 (-0.02%) 5:26 PM ET
3-Hold of 5 3
B Value F Growth B Momentum C VGM
Fundamental Charts
About Cash from Investing (Quarterly)
The company's quarterly Cash from Investing value is the sum of the company's current quarter cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
UTHR 237.00 +2.53(1.08%)
Will UTHR be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for UTHR based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for UTHR
Will United Therapeutics (UTHR) Beat Estimates Again in Its Next Earnings Report?
United Therapeutics (UTHR) Earnings Expected to Grow: Should You Buy?
UTHR: What are Zacks experts saying now?
Zacks Private Portfolio Services
Why Is Jazz (JAZZ) Up 1.3% Since Last Earnings Report?
Why Is Esperion Therapeutics (ESPR) Up 2% Since Last Earnings Report?
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick
Other News for UTHR
Doctors perform first combined heart pump and pig kidney transplant surgery
United Therapeutics Announces World’s First Successful Xenothymokidney Transplant
United Therapeutics Corporation to Report First Quarter 2024 Financial Results Before the Market Opens on Wednesday, May 1, 2024
Noteworthy Wednesday Option Activity: UTHR, ACN, PI
Analysts Offer Insights on Healthcare Companies: United Therapeutics (UTHR) and Addus Homecare (ADUS)